PCVX
Vaxcyte Inc
56.50$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Vaxcyte Inc (PCVX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -513 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.8 | -14 | -9.5 | -14 | -14 | -9.2 | -13 | -11 | -13 | -29 | -28 | -51 | -28 | -39 | -39 | -65 | -48 | -63 | -58 | -129 | -159 | -121 | -61 | -111 | -166 | -121 | -143 | -225 | -281 | -513 | -1,162 | |
| 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.5 | 0.9 | 0.9 | 1.2 | 2.4 | 2.2 | 2.4 | 2.3 | 2.3 | 2.4 | 2.5 | 2.9 | 3.1 | 3.5 | 4.5 | 4.8 | 4.9 | 5.0 | 5.2 | 9.8 | 5.9 | 5.9 | 27 | |
| 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 1.3 | 1.8 | 1.9 | 1.9 | 2.8 | 2.9 | 3.2 | 4.1 | 5.9 | 6.6 | 7.0 | 9.6 | 13 | 13 | 13 | 18 | 22 | 21 | 24 | 31 | 37 | 35 | 36 | 38 | 79 | 188 | |
| 0.0 | -1.2 | -0.6 | – | 0.6 | 1.6 | 1.9 | 1.9 | 2.0 | 3.1 | 3.0 | 3.7 | 4.2 | 6.2 | 6.6 | 14 | 9.6 | 0.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 3.6 | -2.0 | 2.1 | 0.2 | 13 | 9.2 | 5.8 | 7.7 | 5.5 | -9.0 | -6.1 | -27 | 4.4 | 1.0 | 11 | -3.3 | 6.8 | 2.5 | 34 | 38 | -74 | -7.8 | 29 | -2.5 | -50 | 34 | 32 | 3.7 | -2.9 | -34 | -0.7 | |
| 0.0 | 0.2 | 0.1 | 1.0 | 0.3 | 0.1 | 0.0 | 0.7 | 1.2 | 2.2 | 1.7 | 1.4 | 2.9 | 0.9 | 0.8 | 1.1 | 5.6 | 2.1 | 7.3 | 57 | 12 | 45 | 38 | 30 | 27 | 20 | 12 | 5.6 | 15 | 19 | 52 | |
| 0.0 | -0.2 | -0.1 | -1.0 | -0.3 | -0.1 | 0.0 | -0.7 | -173 | -21 | -18 | 0.1 | 50 | 26 | 35 | -36 | -448 | -334 | 22 | -14 | -451 | -80 | -917 | -557 | 123 | 78 | 121 | 115 | -233 | -86 | -83 | |
| – | – | – | – | – | – | – | 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | 43 | 110 | – | – | 0.4 | 0.5 | 0.5 | 7.6 | 0.9 | 3.4 | 50 | -0.9 | 1.0 | -0.7 | -0.2 | -2.6 | 5.6 | -3.3 | -0.6 | 5.5 | – | – | – | – | – | – | – | – | |
| -0.1 | -0.1 | -0.1 | – | -0.1 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | -0.1 | 0.4 | 41 | 110 | 264 | 0.0 | 0.6 | 0.5 | 1.0 | 7.6 | 8.8 | 111 | 50 | 44 | 657 | 42 | 547 | 49 | 2.7 | 818 | 110 | 1,515 | 4.9 | 0.8 | 2.5 | -3.7 | 2.4 | 602 | 607 | 1,208 | |
| -9.9 | -14 | -9.2 | 26 | 96 | 255 | -13 | -11 | -186 | -48 | -39 | -43 | 133 | 36 | 40 | 556 | -454 | 151 | 14 | -148 | 214 | -93 | 532 | -662 | -41 | -40 | -26 | -107 | 87 | 9.2 | -37 | |
| -9.8 | -14 | -9.5 | -15 | -14 | -9.2 | -13 | -11 | -14 | -31 | -30 | -52 | -31 | -40 | -39 | -66 | -53 | -61 | -65 | -186 | -171 | -167 | -99 | -141 | -193 | -102 | -155 | -219 | -295 | -532 | -1,202 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.